Cronos Group (CRON) Q1 2025 earnings summary

Executive summary

• Net revenue rose 28% year-over-year to $32.3M, driven by strong cannabis flower sales in Israel and higher extract sales in Canada, with SpinachⓇ and PEACE NATURALS® brands achieving leading market positions.

• Gross profit increased 206% to $13.7M, with gross margin expanding to 43% from 18% in the prior year; adjusted gross margin reached 44%.

• Net income was $7.7M, reversing a net loss of $2.5M in Q1 2024; adjusted EBITDA improved to $2.3M, up $13M year-over-year.

• Cronos GrowCo expansion is on track for Q2 2025 completion, expected to address supply constraints and fuel further growth in H2 2025.

• Board authorized a $50M share repurchase program, and Anna Shlimak was appointed CFO in March 2025.

Financial highlights

• Q1 2025 net revenue: $32.3M, up 28% year-over-year; Cronos GrowCo contributed $2.9M.

• Gross profit: $13.7M (43% margin); adjusted gross profit: $14.3M (44% margin), up from 18% in Q1 2024.

• Net income: $7.7M (vs. $(2.5)M prior year); adjusted EBITDA: $2.3M (vs. $(10.7)M prior year).

• Cash and short-term investments: $838M as of March 31, 2025.

• Operating expenses decreased 13% year-over-year to $17.8M.

Outlook and guidance

• GrowCo expansion to complete in Q2 2025, with initial sales in H2 2025, expected to alleviate supply constraints and support international growth.

• Operating expenses expected to be higher in the remainder of 2025 compared to Q1, but flat year-over-year.

• Gross margin expected to normalize, with blended Q4 2024 and Q1 2025 margins indicative of underlying business performance.

• CapEx will remain elevated until GrowCo expansion is completed, then normalize lower.

• Management remains focused on revenue growth, margin expansion, and disciplined cost management.